Relationship between mean follow-up intraocular pressure, rates of visual field progression and current target intraocular pressure guidelines.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
02 2022
Historique:
received: 02 07 2020
revised: 10 10 2020
accepted: 13 10 2020
pubmed: 2 11 2020
medline: 23 4 2022
entrez: 1 11 2020
Statut: ppublish

Résumé

To investigate if eyes presenting intraocular pressure (IOP) within the limits of current guideline-driven target IOP indeed experience slow rates of glaucomatous visual field (VF) progression. A total of 8598 24-2 VF tests from 603 eyes from the African Descent and Glaucoma Evaluation Study with manifest glaucoma were included. The sample was split into three groups based on baseline VF mean deviation (MD): G1 (better than -5.0 dB), G2 (-5.0 to -10 dB) and G3 (worse than -10 dB). We investigated the relationship between existing target IOP guidelines and rates of MD progression in these groups. For stable eyes, the medians and IQR of the mean follow-up IOP were G1=15.0 mmHg (IQR: 13.1 to 17.7), G2=13.2 mmHg (IQR: 11.6 to 14.3) and G3=11.9 mmHg (IQR: 10.1 to 13.8) (p<0.01). When considering the mean follow-up IOP within the limits proposed by current guidelines, the median MD slopes were: -0.20 dB/y (IQR: -0.43 to -0.02) for G1<21 mmHg, -0.19 dB/y (IQR: -0.51 to -0.01) for G2<18 mmHg and -0.15 dB/y (IQR: -0.47 to 0.05) for G3<15 mmHg (p=0.63). There were no significant differences between racial groups. In a sample of patients with manifest glaucoma, despite substantial variability between eyes, adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease. clinicaltrials.gov Identifier: NCT00221923.

Identifiants

pubmed: 33130556
pii: bjophthalmol-2020-317406
doi: 10.1136/bjophthalmol-2020-317406
doi:

Banques de données

ClinicalTrials.gov
['NCT00221923']

Types de publication

Clinical Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-233

Subventions

Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019869
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY008208
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY014267
Pays : United States
Organisme : NEI NIH HHS
ID : K23 EY013959
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025253
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Bruna Melchior (B)

Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA.
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

Carlos Gustavo De Moraes (CG)

Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA demoraesmd@gmail.com.

Jayter S Paula (JS)

Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

George A Cioffi (G)

Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA.

Christopher A Girkin (CA)

Department of Ophthalmology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Massimo A Fazio (MA)

Department of Ophthalmology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Robert N Weinreb (R)

Hamilton Glaucoma Center, Department of Ophthalmology, University of California San-Diego, La Jolla, California, USA.

Linda M Zangwill (L)

Hamilton Glaucoma Center, Department of Ophthalmology, University of California San-Diego, La Jolla, California, USA.

Jeffrey M Liebmann (J)

Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH